Document is current

Article History

Received: 11 December 2019

Accepted: 26 June 2020

First Online: 14 August 2020

Ethics approval and consent to participate

: The ethics application process differs among participating registries/countries in ISAR. Within some registries, ethics approval is required at each individual satellite site, whereas for other collaborators, a central ethics committee can process applications on behalf of all satellite sites.Informed consent will be obtained from patients where required to allow anonymised data sharing for approved research projects in ISAR.

: Not applicable.

: AHM-vdZ declares unrestricted grants from GlaxoSmithKline, Novartis and Boehringer Ingelheim, personal fees for advisory board activities from AstraZeneca and a travel grant from Chiesi. AA has received lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Norameda, Novartis and Orion; sponsorships from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Norameda and Novartis; and has been a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva. AM-G declares grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Hoffman La Roche; consultancy agreements with AstraZeneca, Sanofi and Vectura; attendance at advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi and Teva; received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva and Vectura; and attended international conferences for Boehringer Ingelheim and Teva. AB has received speaker fees and grants to his institution from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis for unrelated projects. CMP, DL, GC, JB, JMF, MS, RBM, TAP, TL, UB, VB and YSC have no relevant conflicts of interest. CKR declares consultancy and lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MSD, Mundipharma, Novartis, Sandoz, Takeda and Teva-Handok. CAP, IC, LB2, NE, NH and VC are employees of Optimum Patient Care, a co-funder of the International Severe Asthma Registry. DJJ has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Napp Pharmaceuticals, Chiesi and Novartis and research grant funding from AstraZeneca. DBP declares board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp Pharmaceuticals, Novartis and Teva; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp Pharmaceuticals, Novartis, Pfizer, Teva and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd., AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp Pharmaceuticals, Novartis, Pfizer, Respiratory Effectiveness Group, Teva, Theravance, UK National Health Service and Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma and Teva; payment for manuscript preparation from Mundipharma and Teva; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp Pharmaceuticals, Novartis and Teva; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva and Zentiva; stock/stock options from AKL Research and Development Ltd., which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd. (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd. (Singapore); and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment. EH has been on advisory boards for Sanofi-Genzyme, GlaxoSmithKline, Novartis, Circassia and Nestlè Purina. EW has received advisory board fees from AstraZeneca. She has been an investigator on clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Teva and National Institute of Allergy and Infectious Diseases (NIAID), for which her institution has received funding. BGC reports personal fees and non-financial support from Novartis, grants and personal fees from AstraZeneca, Chiesi and Menarini; personal fees and non-financial support from Teva, grants from Boehringer Ingelheim and personal fees from Sanofi and Mundipharma, outside the submitted work. GWC has received research grants as well as lecture or advisory board fees from Menarini, Alk-Abello, Allergy Therapeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher and Valeas. GB has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva. He is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva. JZ, MA and TNT are employees of AstraZeneca, a co-funder of the International Severe Asthma Registry. LL declares personal fees for consultancy and lectures from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion Pharma, Sanofi and Teva. LB1 has (in the last three years) received lecture or advisory board fees from Alk-Abello, AstraZeneca, Boehringer, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Genzyme/Regeneron and Teva. LGH declares he has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis and Teva; he has taken part in asthma clinical trials sponsored by Boehringer Ingelheim, Hoffmann la Roche and GlaxoSmithKline, for which his institution received remuneration; and he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche and Janssen. LP declares non-financial support, personal fees and grants from Teva; non-financial support and personal fees from Boehringer Ingelheim, Esteve, GlaxoSmithKline, Mundipharma and Novartis; personal fees and grants from AstraZeneca and Chiesi; personal fees from Sanofi and non-financial support from Menarini, outside the submitted work. MH declares grants and other advisory board fees (made to his institutional employer) from AstraZeneca, GlaxoSmithKline, Novartis and Seqirus for unrelated projects. MP declares personal fees and non-financial support from AstraZeneca and GlaxoSmithKline. MEW reports receiving consulting honoraria from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi and Teva. MSK has been a member of advisory boards for AstraZeneca, GlaxoSmithKline and Sanofi and has received honoraria from AstraZeneca, GlaxoSmithKline and Sanofi. NP declares speaker fees and grants to his institution from AstraZeneca, GlaxoSmithKline and Novartis for unrelated projects. PEP declares speaker fees and grants to his institution from AstraZeneca, GlaxoSmithKline and Novartis for unrelated projects. PG declares speaker fees and grants to his institution from AstraZeneca, GlaxoSmithKline and Novartis for unrelated projects. RWC has received honoraria for lectures from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva. He is a member of advisory boards for GlaxoSmithKline and Novartis, has received grant support from GlaxoSmithKline and Aerogen and has patents in the use of acoustics in the diagnosis of lung disease, assessment of adherence and prediction of exacerbations. RJ declares grants from Novartis, GlaxoSmithKline and AstraZeneca; personal fees for consultancy and speaker fees or travel support from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Nutricia, OPRI and Pfizer. TI declares grants from Astellas, Boehringer Ingelheim, Daiichi-Sankyo, Kyorin, Meiji Seika Pharma and Teijin Pharma and lecture fees from Kyorin. YT declares honoraria from Kyorin Pharma and Teijin Pharma and research funding from Kyorin and Meiji Seika Pharma.